Does withdrawal of once-weekly subcutaneous semaglutide 2.4 milligrams lead to weight regain and reversal of cardiometabolic benefits in adults with obesity?

In adults with obesity, stopping semaglutide 2.4 mg led to regain of about two-thirds of lost weight and reversal of most cardiometabolic improvements by one year.

Secondary analysis of RCT · Diabetes Obes Metab 2022

Reference: Wilding JP, Batterham RL, Davies M. Diabetes Obes Metab. 2022; PMID:35441470

Chapters

0:00 Intro

0:38 The trial

3:18 My take

3:46 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en